Nutritional & pharmacologic management of hyperlipoproteinemia.
The results of the nutritional intervention on one of the twenty MRFIT centers is presented. The reduction in cholesterol was 5.78% after four years. Those results were compared with the changes found in serum cholesterol with a similar diet and the administration of either clofibrate or gemfibrozil. The reduction with clofibrate remained at 5%. However with gemfibrozil the reduction in cholesterol was 16%. The HDL level rose in half of these patients treated with either clofibrate or gemfibrozil. The results without concurrent dietary restriction usually show a greater reduction in VLDL and a greater rise in HDL than we found when nutritional and pharmacologic intervention were combined.
D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002994:Clofibrate / Q000627:therapeutic use*; D004041:Dietary Fats / Q000008:administration & dosage*; D015248:Gemfibrozil; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008079:Lipoproteins, VLDL / Q000097:blood; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*
D002791:Cholesterol, Dietary; D004041:Dietary Fats; D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL; D010421:Pentanoic Acids; D014631:Valerates; D002784:Cholesterol; D002994:Clofibrate; D015248:Gemfibrozil